Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Dr. Sabine Mai
Manitoba Institute of Cell Biology, Winnipeg, MB
The proposed study focuses on ependymoma, a childhood brain tumour. At diagnosis, it is not possible to know which child will respond to treatment and which child will recur, i.e. if prognosis is favourable or non-favourable. We have developed quantitative tools that may allow for the distinction of good and poor responders at diagnosis.
These tools involve three-dimensional (3D) imaging of telomeres. Telomeres are the ends of chromosomes; they protect the chromosomes from damage and prevent recombination and fusion with other chromosomes (Mai, 2010). Telomere dysfunction therefore is associated with genomic instability and found in many cancers (Mai and Garini, 2006; Mai, 2010).
The data obtained in this study are quantitatively measured, and the output is expected to be a 3D nuclear telomeric profile of each child’s tumour, indicative of favourable or non-favourable disease and will, in the near future, enable for the first time a choice for specific treatments for each child’s ependymoma.
“I look better than ever!” – it’s a statement you might hear when someone is newly retired and finally has the time to workout and eat properly. But for Brian Cole, it’s what comes after that exclamation that sets him apart. “I look better than ever!” he says, continuing, “but I have terminal brain cancer and might not see my retirement now.”Learn more
Over the past two years, Finley has gone through more than what most people do their entire lives – and his brain tumour journey...Learn more
Dave and I would often comment to each other how lucky we were to not have experienced any major life changing events in our lives. My...Learn more